Significance of Metformin Use in Diabetic Kidney Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jun 18

PMID 32545901

Citations 26

Authors

Daiji Kawanami

Yuichi Takashi

Makito Tanabe

Affiliations

Soon will be listed here.

Abstract

Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D). Based on its various pharmacologic actions, the renoprotective effects of metformin have been extensively studied. A series of experimental studies demonstrated that metformin attenuates diabetic kidney disease (DKD) by suppressing renal inflammation, oxidative stress and fibrosis. In clinical studies, metformin use has been shown to be associated with reduced rates of mortality, cardiovascular disease and progression to end-stage renal disease (ESRD) in T2D patients with chronic kidney disease (CKD). However, metformin should be administered with caution to patients with CKD because it may increase the risk of lactic acidosis. In this review article, we summarize our current understanding of the safety and efficacy of metformin for DKD.

Citing Articles

To target cellular senescence in diabetic kidney disease: the known and the unknown.

Wei Y, Mou S, Yang Q, Liu F, Cooper M, Chai Z Clin Sci (Lond). 2024; 138(16):991-1007.

PMID: 39139135 PMC: 11327223. DOI: 10.1042/CS20240717.

Nutritional Strategies against Diabetic Nephropathy: Insights from Animal Studies and Human Trials.

Zhou J, Franceschini N, Townley-Tilson W, Maeda-Smithies N Nutrients. 2024; 16(12).

PMID: 38931271 PMC: 11206721. DOI: 10.3390/nu16121918.

Individuals Diagnosed With Type 2 Diabetes Mellitus and the Status of Vitamin B12 Deficiency: A Review.

Batulwar P, Anjankar A Cureus. 2024; 16(2):e55103.

PMID: 38558585 PMC: 10978817. DOI: 10.7759/cureus.55103.

Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities.

Yi M, Cruz Cisneros L, Cho E, Alexander M, Kimelman F, Swentek L Int J Mol Sci. 2024; 25(2).

PMID: 38255895 PMC: 10815857. DOI: 10.3390/ijms25020821.

The Role and Mechanism of Metformin in Inflammatory Diseases.

Lin H, Ao H, Guo G, Liu M J Inflamm Res. 2023; 16:5545-5564.

PMID: 38026260 PMC: 10680465. DOI: 10.2147/JIR.S436147.

References

Zhai L, Gu J, Yang D, Hu W, Wang W, Ye S . Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats. J Diabetes. 2016; 9(5):510-517. DOI: 10.1111/1753-0407.12437. View

Pan Q, Li W, Wang H, Sun Q, Xiao X, Brock B . Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell. Horm Metab Res. 2009; 41(11):799-804. DOI: 10.1055/s-0029-1234043. View

de Jager J, Kooy A, Lehert P, Bets D, Wulffele M, Teerlink T . Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2004; 257(1):100-9. DOI: 10.1111/j.1365-2796.2004.01420.x. View

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

Honda T, Hirakawa Y, Nangaku M . The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019; 38(4):414-426. PMC: 6913586. DOI: 10.23876/j.krcp.19.063. View

Mofo Mato E, Guewo-Fokeng M, Essop M, Owira P . Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. Medicine (Baltimore). 2018; 97(27):e11349. PMC: 6076123. DOI: 10.1097/MD.0000000000011349. View

Ekstrom N, Schioler L, Svensson A, Eeg-Olofsson K, Jonasson J, Zethelius B . Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012; 2(4). PMC: 3400073. DOI: 10.1136/bmjopen-2012-001076. View

Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G . Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in.... Nutr Metab Cardiovasc Dis. 2019; 29(11):1127-1150. DOI: 10.1016/j.numecd.2019.07.017. View

Lee E, Jeong J, Chang J, Yang W, Kim S, Park S . Activation of AMP-activated protein kinase inhibits albumin-induced endoplasmic reticulum stress and apoptosis through inhibition of reactive oxygen species. Nephron Exp Nephrol. 2012; 121(1-2):e38-48. DOI: 10.1159/000342802. View

10.

Rhee C, Kalantar-Zadeh K . Diabetes mellitus: Complex interplay between metformin, AKI and lactic acidosis. Nat Rev Nephrol. 2017; 13(9):521-522. PMC: 5922434. DOI: 10.1038/nrneph.2017.105. View

11.

Zhang G, Ma Y, Xi D, Rao Z, Sun X, Wu X . Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. Biopharm Drug Dispos. 2018; 40(1):3-11. DOI: 10.1002/bdd.2164. View

12.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

13.

Podgorski P, Konieczny A, Lis L, Witkiewicz W, Hruby Z . Glomerular podocytes in diabetic renal disease. Adv Clin Exp Med. 2019; 28(12):1711-1715. DOI: 10.17219/acem/104534. View

14.

Matoba K, Takeda Y, Nagai Y, Kawanami D, Utsunomiya K, Nishimura R . Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. Int J Mol Sci. 2019; 20(14). PMC: 6678414. DOI: 10.3390/ijms20143393. View

15.

Packer M . Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework. Diabetes Obes Metab. 2020; 22(5):734-742. DOI: 10.1111/dom.13961. View

16.

Hung S, Chang Y, Liu J, Kuo K, Chen Y, Hsu C . Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015; 3(8):605-14. DOI: 10.1016/S2213-8587(15)00123-0. View

17.

Kume S, Araki S, Ugi S, Morino K, Koya D, Nishio Y . Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2018; 10(4):1032-1040. PMC: 6626952. DOI: 10.1111/jdi.12977. View

18.

Becker M, Visser L, van Schaik R, Hofman A, Uitterlinden A, Stricker B . Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009; 58(3):745-9. PMC: 2646075. DOI: 10.2337/db08-1028. View

19.

Opazo-Rios L, Mas S, Marin-Royo G, Mezzano S, Gomez-Guerrero C, Moreno J . Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. Int J Mol Sci. 2020; 21(7). PMC: 7177360. DOI: 10.3390/ijms21072632. View

20.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View